Company Profile
S.Biomedics CO., LTD., a biopharmaceutical company provides the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury.
Its portfolio also includes TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease, FECS-Ad, which is 1/2a for the treatment of critical limb ischemia, FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet, TED-R for the treatment of macular degeneration, CF-TED-N for the treatment of stroke, and CF-FECS-DF for the treatment of wound.
The company provides testing services; and owns platform technologies for developing cell therapy products. The company has a strategic partnership with Catalent, Inc. for the development and manufacturing of TED-A9. Founded in 2005, S.Biomedics is headquartered in Seoul, South Korea.